HIV visceral fat trial
In a multicentre, randomised, double-blind, placebo-controlled trial in adults with HIV-associated abdominal fat accumulation (26-week primary period plus 26-week safety extension), subcutaneous tesamorelin produced a significant reduction in visceral adipose tissue as measured by CT scan, with associated IGF-1 elevation and improvement in some cardiometabolic markers, and no significant change in subcutaneous fat or BMI versus placebo.
- Study type
- Human trial
- Population
- Human, HIV-infected adults with abdominal fat accumulation, multicentre, randomised double-blind placebo-controlled, 26-week primary plus 26-week extension
- Source
- 1 Falutz et al., 2007
Limitation: Population specific to HIV-associated lipodystrophy; findings should not be generalised to visceral-fat reduction in the general non-HIV population without a separate supporting study.